GPX4 Inhibitor Screening Assay Kit

Cayman's GPX4 Inhibitor Screening Assay Kit provides a robust and easy-to-use platform for identifying novel inhibitors of human GPX4, a negative regulator of the ferroptosis pathway. The assay measures GPX4 indirectly by a coupled reaction with glutathione reductase (GR). Oxidized glutathione (GSSG), produced upon reduction of hydroperoxide by GPX4, is recycled to its reduced state by GR and NADPH. The oxidation of NADPH to NADP⁺ is accompanied by a decrease in absorbance at 340 nm. The rate of decrease in A₃₄₀ is directly proportional to GPX4 activity. The GPX4 inhibitor ML-162 is included as a positive control.

Needed but not supplied: Please download the kit booklet to verify if UltraPure Water (Milli-Q or equivalent) or any other components are needed for this assay.

WARNING This product is not for human or veterinary use.

Yong, Y., Yan, L., Wei, J., et al. A novel ferroptosis inhibitor, Thonningianin A, improves Alzheimer’s disease by activating GPX4. Theranostics 14(16), 6161-6184 (2024).

Chen, T., Leng, J., Tan, J., et al. Discovery of novel potent covalent glutathione peroxidase 4 inhibitors as highly selective ferroptosis inducers for the treatment of triple-negative breast cancer. J. Med. Chem. 66(14), 10036-10059 (2023).